Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | FPR2 | P25090 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.43 |
| ▸ | NPY4R | P50391 | 3/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.42 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13033321 | 0.89 | MEN1 (0.56) | TGM2FPR2MEN1USP2POLB | |
| SCHEMBL25698360 | 0.89 | TGM2 (0.57) | TGM2FPR2MEN1USP2POLB | |
| SCHEMBL17348121 | 0.88 | TGM2 (0.55) | TGM2FPR2MEN1USP2POLB | |
| SCHEMBL18760308 | 0.87 | USP2 (0.54) | TGM2FPR2MEN1USP2POLB | |
| SCHEMBL12017845 | 0.85 | MEN1 (0.53) | TGM2FPR2MEN1USP2POLB | |
| SCHEMBL18760518 | 0.85 | FPR2 (0.56) | TGM2FPR2MEN1USP2POLB | |
| SCHEMBL9007850 | 0.85 | USP2 (0.59) | TGM2FPR2MEN1USP2POLB | |
| SCHEMBL12118351 | 0.85 | MEN1 (0.59) | TGM2FPR2MEN1USP2POLB | |
| SCHEMBL10000831 | 0.84 | P2RY6 (0.56) | TGM2FPR2MEN1USP2POLB | |
| SCHEMBL17662505 | 0.84 | TGM2 (0.53) | TGM2FPR2MEN1USP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403987-B2 | Charged particles | BASF SE (DE) | 2016-08-02 | — | — | US | disclosed |
| US-20120229884-A1 | CHARGED PARTICLES | BASF SE (DE) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120229884-A1 | CHARGED PARTICLES | POLE3, POLD3, IPO4 | TGM2 4224/4885FPR2 4741/4885MEN1 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.